Phil B.FontanarosaMD, Deputy EditorIndividualAuthorMargaret A.WinkerMD, Deputy EditorIndividualAuthorStephen J.LurieMD, PhD, Fishbein FellowIndividualAuthor
Copyright 2000 American Medical Association. All Rights Reserved.
Applicable FARS/DFARS Restrictions Apply to Government Use.2000
To the Editor: Dr Heymann and colleagues1 emphasized the need for global action against drug-resistant
tuberculosis (TB). We agree that this should be an important part of a comprehensive
action plan aimed at controlling and eventually eliminating TB, but we have
2 points of disagreement. First, we disagree with their claim that "where
effective DOTS [directly observed treatment, short-course] programs have been
in place . . . ," multidrug-resistant TB (MDRTB) "remained unchanged or increased."
Contrary to their mention of Korea as having an "effective DOTS program" that
has not altered "the prevelance of MDRTB," reports in Korea's regular nationwide
prevalence surveys show a decrease in both TB prevalence from 668 per 100,000
in 1965 to 93 per 100,000 in 1995 and its drug resistance, from 38% in 1965
to 9.9% in 1995.2
Schraufnagel D, Abubaker J. Global Action Against Multidrug-Resistant Tuberculosis. JAMA. 2000;283(1):54-55. doi:10-1001/pubs.JAMA-ISSN-0098-7484-283-1-jbk0500